IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis

Shigeru Kotake,1 Nobuyuki Udagawa,2 Naoyuki Takahashi,2 Kanami Itoh,2 Shigeru Ishiyama,3 Seiji Saito,1 Kazuhiko Inoue,1 Naoyuki Kamatani,1 Matthew T. Gillespie,4 T. John Martin,4 and Tatsuo Suda2

1The Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo 162-0054, Japan
2Department of Biochemistry, School of Dentistry, Showa University, Tokyo 142-8555, Japan
3The Second Department of Pathology, Tokyo Women’s Medical University, Tokyo 162-0054, Japan
4St. Vincent’s Institute of Medical Research, Fitzroy, Victoria 3065, Australia

Address correspondence to: Tatsuo Suda, Department of Biochemistry, School of Dentistry, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan. Phone: 81-3-3784-8163; Fax: 81-3-3784-5555; E-mail: suda@dent.showa-u.ac.jp

Received for publication November 3, 1998, and accepted in revised form March 22, 1999.

IL-17 is a newly discovered T cell–derived cytokine whose role in osteoclast development has not been fully elucidated. Treatment of cocultures of mouse hemopoietic cells and primary osteoblasts with recombinant human IL-17 induced the formation of multinucleated cells, which satisfied major criteria of osteoclasts, including tartrate-resistant acid phosphatase activity, calcitonin receptors, and pit formation on dentine slices. Direct interaction between osteoclast progenitors and osteoblasts was required for IL-17–induced osteoclastogenesis, which was completely inhibited by adding indomethacin or NS398, a selective inhibitor of cyclooxygenase-2 (COX-2). Adding IL-17 increased prostaglandin E2 (PGE2) synthesis in cocultures of bone marrow cells and osteoblasts and in single cultures of osteoblasts, but not in single cultures of bone marrow cells. In addition, IL-17 dose-dependently induced expression of osteoclast differentiation factor (ODF) mRNA in osteoblasts. ODF is a membrane-associated protein that transduces an essential signal(s) to osteoclast progenitors for differentiation into osteoclasts. Osteoclastogenesis inhibitory factor (OCIF), a decoy receptor of ODF, completely inhibited IL-17–induced osteoclast differentiation in the cocultures. Levels of IL-17 in synovial fluids were significantly higher in rheumatoid arthritis (RA) patients than osteoarthritis (OA) patients. Anti–IL-17 antibody significantly inhibited osteoclast formation induced by culture media of RA synovial tissues. These findings suggest that IL-17 first acts on osteoblasts, which stimulates both COX-2–dependent PGE2 synthesis and ODF gene expression, which in turn induce differentiation of osteoclast progenitors into mature osteoclasts, and that IL-17 is a crucial cytokine for osteoclastic bone resorption in RA patients.


Introduction
Bone-resorbing osteoclasts are of hemopoietic cell origin, probably of the CFU-M–derived monocyte-macrophage family (1). Osteoclasts are large multinucleated giant cells that express tartrate-resistant acid phosphatase (TRAP) activity and calcitonin receptors and have the ability to form resorption pits on dentine slices (2–4). In the process of osteoclast differentiation, there is an absolute requirement for cell-cell contact between osteoclast progenitors and bone marrow stromal cells or calvaria-derived osteoblasts (5–8).

We developed a mouse coculture system of hemopoietic cells and primary osteoblasts to investigate osteoclast formation in vitro. In this coculture system, several systemic and local factors were capable of inducing osteoclast-like multinucleated cell (OCL) formation (6–9). These bone-resorbing factors were classified into 3 categories according to their signal transduction pathways: (a) 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3] induced OCL formation via the A kinase system; and (c) IL-11, oncostatin M, leukemia inhibitory factor, and IL-6 in the presence of soluble IL-6 receptors, all of which transduce their signals through a signal-transducing gp130 protein, also induced OCL formation in vitro. We reported previously that the target cells of IL-6 are osteoblasts/stromal cells but that they are not osteoclast precursors in inducing osteoclast differentiation (10). Similarly, coculture experiments using VDR knockout mice and PTH/PTHrP receptor knockout mice have indicated that the signals mediated by 1α,25(OH)2D3 and PTH, respectively, are also transduced into osteoblasts/stromal cells, but not into osteoclast precursors, to induce osteoclast formation (11, 12). Thus, it is concluded that the signals induced by all bone-resorbing factors are transduced into osteo-blasts/stromal cells to induce osteoclast formation. Our hypothesis proposes that osteoblasts/stromal cells express a critical common mediator named osteoclast differentiation factor (ODF), a membrane-bound factor that promotes differentiation of osteoclast progenitors into osteoclasts in response to various bone-resorbing factors through a mechanism involving cell-cell contact (6, 8).
Tsuda et al. (13) recently cloned an osteoclastogenesis inhibitory factor (OCIF) that markedly inhibited OCL formation in mouse cocultures. OCIF was identical to osteoprotegerin (OPG) (14, 15) and TR1 (16, 17). OCIF/OPG/TR1 was a secreted member of the TNF receptor family and inhibited osteoclast differentiation by preventing cell-cell interaction between osteoclast progenitors and bone marrow–derived stromal cells (13–15, 17). Discovery of OCIF facilitated the molecular cloning of ODF, which stimulated OCL differentiation in the absence of stromal cells (18). ODF was a ligand of OCIF and was found to be identical to TRANCE/RANKL/OPGL (18–21). TRANCE increased dendritic cell–mediated T-cell proliferation (22). Thus, ODF appears to be an important regulator of both osteoclastogenesis and immune response.

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by the destruction of articular cartilage and bone (23). The levels of monocyte-macrophage–derived cytokines such as IL-1, IL-6, and soluble IL-6 receptor are elevated in the synovial fluids of RA patients, suggesting that osteoclastogenesis occurs in the joints (24). The role of T cells in the pathogenesis of RA at the chronic stage, however, has not yet been determined, because T cell–derived cytokines such as IL-2 or IFN-γ are hardly detectable in the synovial tissues and fluids (25, 26).

IL-17 is a recently cloned cytokine that is secreted by activated memory CD4+ T cells and modulates the early stage of immune responses (27). Rouvier et al. (28) have cloned cytotoxic T lymphocyte–associated antigen-8 (rat IL-17) from a T-cell subtraction library. Mouse IL-17 was subsequently cloned from a thymus-derived, activated T-cell cDNA library (29). Furthermore, 2 independent groups have cloned the human counterpart of mouse IL-17 (30–32). Fossiez et al. (32) reported that IL-17 stimulated epithelial, endothelial, and fibroblastic stromal cells to secrete several cytokines, including IL-6, IL-8, G-CSF, and PGE2. In addition, IL-17 greatly promoted the proliferation of CD34+ hemopoietic progenitors in cocultures of synovial fibroblastic cells collected from patients with RA (32). These findings suggest that IL-17 may be a major regulator responsible for the communication between T cells and hemopoietic cells.

In the present study, we examined a potential role of IL-17 in osteoclastogenesis using a mouse coculture system. IL-17 greatly stimulated OCL formation via a mechanism involving PGE2 synthesis and ODF gene expression. Also, we show by ELISA that IL-17 levels are significantly elevated in the synovial fluids of RA patients compared with those of osteoarthritis (OA) patients. Anti–IL-17 antibody significantly inhibited OCL formation in cocultures with the culture media of RA synovial tissues. Moreover, immunostaining of the synovial tissues of RA patients demonstrated that IL-17–positive cells are detected in a subset of CD4+, CD45RO+ T cells in these patients. These findings suggest that IL-17 present in the synovial tissues and fluids of RA patients may be involved in joint destruction.

**Methods**

**Animals and drugs.** Five- to 8-week-old male ddY mice and newborn ddY mice were obtained from Shizuoka Laboratories Animal Center (Shizuoka, Japan). Recombinant human IL-17 (rhIL-17) was purchased from PeproTech EC Ltd. (London, United Kingdom). Anti-human IL-17 polyclonal antibody (goat IgG) and recombinant murine TNF-α were purchased from R&D Systems Inc. (Minneapolis, Minnesota, USA). Recombinant human IL-1 receptor β (IL-1Rβ) was purchased from Genzyme Pharmaceuticals (Cambridge, Massachusetts, USA). 1α,25(OH)2D3 and PGE2 were obtained from Wako Pure Chemical Industries Ltd. (Osaka, Japan). Synthetic human PTH(1-34) was provided by Asahi Chemical Industry (Tokyo, Japan). N398 was purchased from Calbiochem-Novabiochem Corp. (La Jolla, California, USA). 125I–labeled human calcitonin was obtained from Amersham Pharmacia Biotech (Buckinghamshire, United Kingdom). Recombinant human OCIF and cDNA probes for mouse ODF and OCIF were provided by Snow Brand Milk Products Co. (Tochigi, Japan) (15, 18, 33). Other chemicals and reagents were of analytical grade.

**Mouse coculture system for osteoclastogenesis.** To prepare primary osteoblasts, a total of 20–30 pieces of calvaria collected from newborn mice were digested with 0.1% collagenase (Wako Pure Chemical Industries Ltd.) to prepare primary osteoblasts, a total of 20–30 pieces of calvaria collected from newborn mice were digested with 0.1% collagenase (Wako Pure Chemical Industries Ltd.).

**Figure 1**

OCL formation in cocultures of mouse bone marrow cells and osteoblasts in the presence of increasing concentrations of IL-17. After culture for 6 days, TRAP-positive OCLs were counted. Data are expressed as the means ± SEM of quadruplicate cultures. Experiments were repeated 10 times with similar results.

**Figure 2**

IL-17 induces OCL formation in cocultures of mouse bone marrow cells and osteoblasts in response to IL-17. (a) Control culture without IL-17. (b) Morphology of OCLs formed in coculture on day 6 in the presence of 1 ng/mL of IL-17. (c) Resorption pits formed on a dentine slice. Scale bars: 200 μm.
Chemical Industries Ltd.) and 0.2% dispase (Godo Shusei, Tokyo, Japan). Bone marrow cells were obtained from adult mice. Osteoblasts were cocultured with bone marrow cells as described (34). In short, primary osteoblasts (2 × 10^4 per well) were cultured with bone marrow cells (5 × 10^4 per well) in 48-well plates (Corning Class Inc., Corning, New York, USA) with 0.3 mL of α-MEM (GIBCO BRL, Gaithersburg, Maryland, USA) containing 100 U/mL of penicillin, 10 μg/mL of streptomycin, and 2 mM l-glutamine for 3 days in 5% CO2 in air at 37°C. Culture supernatants were collected and kept frozen at –80°C until use for measurement of the IL-17 content by an ELISA kit (BioSource International, Camarillo, California, USA). The mean value of the concentration of the IL-17 of 3 synovial pieces from a single joint was calculated. Frozen sections were prepared from each patient and used for immunohistologic and TRAP staining.

The culture media of synovial tissues (40 μl) from RA patients were added together with or without anti-human IL-17 antibody (1 μg/mL) to the cocultures (200 μl) of osteoblasts and bone marrow cells. After culture for 7 days, the number of TRAP-positive OCLs was counted. No OCLs were formed in the control cultures treated with rabbit IgG (5 μg/mL; Endogen Inc., Woburn, Massachusetts, USA). We used the culture media of synovial tissues rather than synovial fluids to examine the effect of cytokines produced by the same amount of synovial tissues collected from different RA patients. IL-17 in the synovial fluids. Synovial fluids were obtained from 43 RA patients, 9 OA patients, 4 trauma patients, and 7 gout patients by arthrocentesis into heparinized vials. The synovial fluids (10 mL) were then treated with hyaluronidase (0.3 mL, 200 U/mL; Mochida, Tokyo, Japan) to reduce viscosity. The amount of IL-17 in the synovial fluids was measured using an ELISA kit (BioSource International) according to the manufacturer’s instructions.

Immunohistologic staining. Specimens of synovial tissue fixed in OCT compound and frozen were cut into sections (7 μm). Endogenous and exogenous peroxidase activities were blocked by placing tissues sections in 1% periodic acid at room temperature for 10 minutes and then washing them thoroughly with PBS. For double staining, anti–IL-17 antibody (R&D Systems Inc.) and CD4, CD8, and CD45RO (DAKO A/S, Glostrup, Denmark) were used as primary antibodies at 1:300 and 1:50 dilutions, respectively, with incubation overnight at 4°C. For the secondary anti-

Figure 3
Effect of neutralizing antibody against IL-17 on OCL formation in cocultures of mouse bone marrow cells and osteoblasts in the presence of IL-17 (1 ng/mL), 1α,25(OH)2D3 (10−4 M), PTH (200 ng/mL), and IL-1β (10 ng/mL). Concentrations of antibody against IL-17 were 2.5 μg/mL for experiments with IL-17 and 5 μg/mL for those with 1α,25(OH)2D3, PTH, and PGE2. After culture for 6 days, TRAP-positive OCLs were counted. Data are expressed as the means ± SEM of quadruplicate cultures. Experiments were repeated 5 times with similar results.

Figure 4
Effect of NS398 (10−8 M) or indomethacin (10−8 M) on OCL formation in cocultures of mouse bone marrow cells and osteoblasts in the presence of IL-17 (1 ng/mL), 1α,25(OH)2D3 (10−4 M), and PGE2 (10−8 M). After culture for 6 days, TRAP-positive OCLs were counted. Data are expressed as the means ± SEM of quadruplicate cultures. Experiments were repeated 7 times with similar results.
body, anti-goat IgG–conjugated peroxidase (Medical and Biological Laboratories, Nagoya, Japan) (1:300 dilution) was first used with incubation at room temperature for 60 minutes, and it developed color using 3,3′-diaminobenzidine tetrahydrochloride (DAB). Next, for the secondary antibody, FITC-conjugated mouse immunoglobulins (DAKOPATTS Japan Ltd., Kyoto, Japan) (1:300 dilution) were used with incubation at room temperature for 3 hours. They were examined by light and fluorescence microscopy.

**Northern blot analysis.** Total cellular RNA was extracted from osteoblasts using Trizol (GIBCO BRL). For Northern blotting, 20 mg of total RNA was resolved by electrophoresis in a 1% agarose-formaldehyde gel and was transferred onto a Hybond-N membrane (Amersham Life Sciences Inc., Arlington Heights, Illinois, USA). The membrane was hybridized with 32P-labeled cDNA probes for mouse ODF (18), OCIF (15), and β-actin. The hybridized probes were removed from the membrane by boiling in 0.2% SDS and then sequentially rehybridized with the respective probes.

**Statistical analysis.** The data were analyzed by a Kruskal-Wallis test, a Mann-Whitney U test, and Student’s t test (StatView; Abacus Concepts Inc., Berkeley, California, USA). The significance of difference was defined as $P < 0.01$. All values were represented as the means ± SEM of quadruplicate cultures. No OCLs were formed in the coculture without the culture media of synovial tissues. *Significantly different from the cultures treated without antibody $P<0.0001$. ND, none detectable.

<table>
<thead>
<tr>
<th>Patients</th>
<th>Concentration of IL-17 in culture media or synovial fluids (pg/ml)</th>
<th>Number of TRAP-positive OCLs formed per well Anti-human IL-17 antibody</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synovial fluids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RA no. 27</td>
<td>5.7</td>
<td>6.7 ± 1.1</td>
</tr>
<tr>
<td>RA no. 60</td>
<td>12.5</td>
<td>12.6 ± 0.7</td>
</tr>
<tr>
<td>RA no. 96</td>
<td>ND</td>
<td>0</td>
</tr>
<tr>
<td>Culture media of synovial tissues</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exp. 1</td>
<td>RA no. 7</td>
<td>16.0</td>
</tr>
<tr>
<td></td>
<td>RA no. 9</td>
<td>35.7</td>
</tr>
<tr>
<td></td>
<td>OA no. 1</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>OA no. 2</td>
<td>ND</td>
</tr>
<tr>
<td>Exp. 2</td>
<td>RA no. 7</td>
<td>16.0</td>
</tr>
<tr>
<td></td>
<td>RA no. 9</td>
<td>35.7</td>
</tr>
<tr>
<td></td>
<td>OA no. 3</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>OA no. 4</td>
<td>ND</td>
</tr>
</tbody>
</table>

The culture media of synovial tissues (40 μl) or synovial fluids (20 μl) from RA or OA patients were added together with (+) or without (−) anti-human IL-17 antibody (1 μg/ml) to the cocultures (200 μl) of osteoblasts and bone marrow cells. After culture for 7 days, the number of TRAP-positive OCLs was counted. Data are expressed as the means ± SEM of quadruplicate cultures. ASignificantly different from the cultures treated without antibody $P<0.0001$. ND, none detectable.

**Figure 5** Effect of NS398 (10−8 M) on OCL formation and PGE2 production in cocultures and separate cultures of osteoblasts and bone marrow cells in the absence or presence of IL-17 (1 ng/ml). After culture for 6 days, TRAP-positive OCLs were counted. Data are expressed as the means ± SEM of quadruplicate cultures. Experiments were repeated 5 times with similar results.

**Figure 6** Effect of OCIF (1.5–50 ng/ml) on OCL formation in cocultures of mouse bone marrow cells and osteoblasts in the presence of IL-17 (1 ng/ml). After culture for 6 days, TRAP-positive OCLs were counted. Data are expressed as the means ± SEM of quadruplicate cultures. Experiments were repeated 3 times with similar results.
The IL-17–induced OCL formation was dose-dependently inhibited by OCIF, a decoy receptor for ODF, which is induced on the plasma membrane of osteoblasts in response to several bone-resorbing factors (Figure 6). This suggests that ODF is a key factor for OCL formation induced by IL-17 as well. Indeed, IL-17 dose-dependently induced ODF mRNA expression in osteoblasts (Figure 7). IL-1β and 1α,25(OH)2D3 also induced ODF mRNA expression in osteoblasts. NS398 inhibited the expression of ODF mRNA by IL-17 (Figure 7). These findings suggest that IL-17–induced OCL formation occurs by a mechanism involving PGE2 production, which in turn stimulates the production of ODF. On the other hand, OCIF mRNA was constitutively expressed in osteoblasts in the presence or absence of bone-resorbing factors (Figure 7).

To examine the role of IL-17 in the pathogenesis of RA, IL-17 in synovial fluids obtained from patients with RA, OA, trauma, or gout was measured. The concentration of IL-17 in the synovial fluids was significantly higher in RA patients than OA patients (P < 0.0001) (Figure 8a). In the culture of synovial tissues, the culture media from RA patients contained significantly more IL-17 than those from OA patients (P = 0.009).

Results

Figure 1 shows TRAP-positive OCL formation in response to IL-17 in cocultures of mouse bone marrow cells and osteoblasts. Treatment with rhIL-17 for the entire 6 days in culture dose-dependently stimulated TRAP-positive OCL formation (Figures 1 and 2b). An autoradiographic study using labeled calcitonin revealed that TRAP-positive multinucleated cells formed in the cocultures possessed calcitonin receptors (data not shown). When bone marrow cells and osteoblasts were cocultured on dentine slices in the presence of IL-17, numerous resorption pits were formed (Figure 2c). A polyclonal anti–IL-17 antibody (at 2.5 μg/mL) completely inhibited the IL-17 effect on OCL formation (Figure 3). A higher concentration (at 5 μg/mL) of IL-17 antibody, however, did not inhibit the OCL formation induced by 1α,25(OH)2D3, PTH, or IL-1.

When osteoblasts and bone marrow cells were cocultured without direct contact using a membrane filter, no TRAP-positive cells were formed in response to IL-17 (data not shown). This indicates that a membrane-associated factor is involved in the IL-17–induced OCL formation. Moreover, the OCL formation induced by IL-17 was completely inhibited by adding indomethacin or NS398, a selective inhibitor of cyclooxgenase-2 (COX-2) (Figure 4). Osteoclastogenesis induced by 1α,25(OH)2D3 or PGE2 was not inhibited by indomethacin or NS398 (Figure 4). These findings suggest that IL-17 induces OCL formation by a mechanism involving PGE2.

Figure 5 shows the amounts of PGE2 released into culture media in cocultures of osteoblasts and bone marrow cells. PGE2 was also measured in separate cultures of osteoblasts or bone marrow cells. rhIL-17 increased the PGE2 content in culture media in separate cultures of osteoblasts, but not of bone marrow cells, and this was further enhanced in the cocultures (Figure 5). The IL-17–induced PGE2 production was correlated with OCL formation in the cocultures. NS398, a COX-2 selective inhibitor, blocked both PGE2 production and OCL formation (Figure 5).
Furthermore, when synovial tissues were immunostained with anti–IL-17 antibody, IL-17–positive mononuclear cells were detected in those from RA patients (Figure 9a) but not in those from OA patients. In general, CD4+ T cells have helper and inducer functions, whereas CD8+ T cells serve as cytotoxic cells. CD4+ and CD8+ T cells are classified into naive and memory T cells by their expression of CD45 isoforms. CD45RA+ and CD45RO+ phenotypes are associated with naive and memory T cells, respectively. In double staining of the synovial tissues with antibodies against CD4, CD8, or CD45RO, as well as IL-17, a subset of CD4+ cells (Figure 9b) and a subset of CD45RO+ cells (Figure 9d) were stained with the antibodies against IL-17. CD8+ cells, however, were not stained with the antibodies against IL-17 (Figure 9c). Fossiez et al. (32) have reported that IL-17 transcripts can be detected only in T cells upon activation, and mostly in activated CD4+, CD45RO+ memory T cells. Thus, our results are consistent with their findings, indicating that a subset of CD4+, CD45RO+ memory T cells produces IL-17 in synovial tissues of RA patients.

Synovial fluids from RA patients induced osteoclastogenesis, which was partially inhibited by adding anti–IL-17 antibody (Table 1). The weak osteoclast-inductive capacity of RA synovial fluids may be due to the presence of potent inhibitors of osteoclastogenesis such as OCIF, nonsteroidal anti-inflammatory drugs like COX inhibitors, and disease-modifying antirheumatic drugs like gold salts. Thus, the culture media of synovial tissues from RA patients were used to test the biologic significance of synovial tissue–derived IL-17 to induce osteoclastogenesis in the coculture experiments. OCLs were formed in cocultures of osteoblasts and bone marrow cells in response to the culture media of synovial tissues from RA patients but not from OA patients (Table 1). The stimulation of OCL formation induced by the culture media was blocked strikingly by adding anti–IL-17 antibody. OCL formation was reduced significantly (80% reduction; \( P < 0.0001 \)), whereas control IgG antibody had no effect (Table 1). OCL formation was not induced in cocultures in the absence of culture media of synovial tissues (data not shown). This indicates the importance of synovial tissue–derived IL-17 in invoking osteoclastogenesis.

**Discussion**

Recent evidence indicates that ODF, a ligand for OCIF, is expressed as a membrane-associated protein in osteoblasts/stromal cells and that it stimulates murine and human OCL formation in the absence of osteoblasts/stromal cells (18, 21, 38). Treatment of osteoblasts with 1\(\alpha\),25(OH)\(_2\)D\(_3\), PTH, PGE\(_2\), or IL-11 upregulates ODF mRNA expression (18). In the present study, we showed that IL-17 similarly stimulated ODF gene expression in osteoblasts and induced osteo-
clast differentiation in cocultures of osteoblasts and bone marrow cells. The osteoclast formation induced by IL-17 was completely blocked by OCIF, a decoy receptor of ODF, which in turn stimulates OCL formation (Figure 10).

We also reported that IL-18 inhibits osteoclast formation via the production of GM-CSF by T cells (34, 39). The precise role of T cells in bone homeostasis, however, has not been fully elucidated. T cell–derived cytokines that inhibit OCL formation, such as IL-4, IL-10, IFN-γ, and GM-CSF, have been reported, but T cell–derived cytokines that induce OCL formation have not been reported before, except for TNF-α. In the present study, we demonstrated that IL-17 is produced by T cells and induces osteoclast formation. Thus, it is likely that IL-17 is an important regulator of both osteoclastogenesis and immune response.

We also reported that OCLs are present in synovial tissues from RA patients and that IL-6 and soluble IL-6 receptors in synovial fluids may be involved in OCL formation (24). It is likely that IL-17 produced by activated memory T cells in synovial tissues also contributes to OCL formation via PGE2 synthesis and ODF expression in synovial tissues. In the present study, we detected a higher concentration of IL-17 in synovial fluids from RA patients compared with those from OA patients. Moreover, anti–IL-17 antibody greatly inhibited OCL formation in cocultures of bone marrow cells and osteoblasts; this antibody was induced by the culture media of synovial tissues from 2 RA patients whose synovial tissues produced a significant amount of IL-17 (Table 1). In fact, approximately 80% of the OCL formation was blocked by adding anti–IL-17 antibody, indicating that IL-17 is indeed involved in OCL formation at least in patients whose synovial tissues produce a significant amount of IL-17. Thus, in the adjacent articular bone, as well as in the synovial tissues, IL-17 may induce OCL formation via PGE2 synthesis and ODF expression by osteoblasts.

The role of T cells in the pathogenesis of chronic RA has been a matter of controversy (25, 26, 40, 41). The paucity of T cell–derived cytokines and the contrasting abundance of monokines have led to the view that RA, at least in its late stage, is a disease in which the key cellular elements are monocytes and synovocytes. Moreover, MacInnes et al. (42) recently demonstrated that IL-15, which functions just like IL-2 despite IL-15 being a monocyte-derived cytokine, plays an important role in inducing synovial T-cell recruitment and activation. In the present study, however, IL-17–positive cells were detected in a subset of CD4+, CD45RO+ T cells in synovial fluids from RA patients. Furthermore, Neidhart et al. (43) have recently shown that in patients with high IgM rheumatoid factors, increases in the number of IL-17 mRNA, CD45RA−, and CD45RO+ memory T cells were correlated with the joint destruction evaluated by Larsen radiographic scores but not with the disease duration. Thus, it is concluded that T cell–derived IL-17 may, at least in part, play a role in joint destruction in RA patients.

In summary, IL-17 acts on osteoblasts, resulting in COX-2–mediated PGE2 synthesis and ODF expression, the latter directly inducing differentiation of osteoclast progenitors into mature osteoclasts by binding to ODF receptors present in osteoclast progenitors. IL-17 appears to be involved in not only immune responses but also osteoclastogenesis in RA patients. Excess production of IL-17 by memory T cells may contribute to osteoclastic bone resorption in RA patients. The control of expression of IL-17, ODF, or OCIF in RA patients will provide direction to the development of new treatment strategies for bone destruction in RA patients.

Acknowledgments
We thank Eijiro Jimi, Taro Tsurukai, Shuichi Akiyama, Toshimasa Shinki (Showa University), and Mariko Sodeoka (Tokyo Women’s Medical University) for their valuable technical assistance. This work was supported in part by grants-in-aid (09677355 and 09677190) and the High-Technology Research Center Project from the ministry of Education, Science, Sport and Culture of Japan, and by grants from the Nakatomi Health Science Foundation and the National Health & Medical Research Council of Australia.

Figure 10
A possible mechanism of osteoclastogenesis by IL-17 in the affected joint of RA patients. IL-17 produced by T cells in the synovial tissues induces PGE2 synthesis in osteoblasts/stromal cells in the adjacent bone. PGE2 then induces ODF expression in osteoblasts. ODF transduces a signal for osteoclastogenesis through ODF receptor (RANK) expressed on osteoclast progenitors (18, 20). M-CSF produced by osteoblasts/stromal cells is also an essential soluble factor for osteoclast differentiation (7, 8, 18).


